2022. Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM). Canadian Hematology Today. 1, S11 (Nov. 2022). DOI:https://doi.org/10.58931/cht.2022.1S1130.